SSGJ-709

N/A

Report date: 2025/12/01 17:17:46

Base Information

Drug NameSSGJ-709

Drug Alias NameSSGJ-709SSGJ709

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-Lymphocyte activation gene 3 proteinAnti-PD-1

TargetsLymphocyte activation gene 3 proteinProgrammed cell death protein 1

Therapy Area/IndicationsSolid tumoursNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustraliaMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesShenyang Sunshine Pharmaceutical Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShenyang Sunshine Pharmaceutical Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumoursNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A